Zacks Research Issues Positive Estimate for Hologic Earnings

Hologic, Inc. (NASDAQ:HOLX) – Equities researchers at Zacks Research upped their Q1 2026 earnings per share (EPS) estimates for shares of Hologic in a report released on Monday, November 24th. Zacks Research analyst Team now expects that the medical equipment provider will earn $1.07 per share for the quarter, up from their prior estimate of $1.06. The consensus estimate for Hologic’s current full-year earnings is $4.28 per share. Zacks Research also issued estimates for Hologic’s Q2 2026 earnings at $1.08 EPS, FY2026 earnings at $4.45 EPS, Q1 2027 earnings at $1.20 EPS, Q2 2027 earnings at $1.26 EPS, FY2027 earnings at $4.92 EPS and FY2028 earnings at $5.35 EPS.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Monday, November 3rd. The medical equipment provider reported $1.13 earnings per share for the quarter, beating the consensus estimate of $1.10 by $0.03. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The company had revenue of $1.05 billion during the quarter, compared to analysts’ expectations of $1.03 billion. During the same quarter in the prior year, the company earned $1.01 earnings per share. The business’s quarterly revenue was up 6.2% compared to the same quarter last year.

HOLX has been the topic of several other research reports. BNP Paribas Exane downgraded Hologic from an “outperform” rating to a “neutral” rating and set a $79.00 price target on the stock. in a research note on Friday, November 21st. Argus boosted their target price on Hologic from $80.00 to $90.00 and gave the company a “buy” rating in a research note on Friday, September 19th. Royal Bank Of Canada raised shares of Hologic from a “sector perform” rating to an “outperform” rating and raised their price target for the stock from $72.00 to $87.00 in a research note on Wednesday, August 6th. Needham & Company LLC restated a “hold” rating on shares of Hologic in a report on Tuesday, November 4th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Hologic in a research note on Friday, October 31st. Five research analysts have rated the stock with a Buy rating and fifteen have issued a Hold rating to the company’s stock. According to MarketBeat, Hologic has a consensus rating of “Hold” and an average target price of $79.67.

Hologic Trading Up 0.2%

HOLX opened at $74.88 on Wednesday. The stock has a market capitalization of $16.69 billion, a P/E ratio of 31.07, a P/E/G ratio of 2.54 and a beta of 0.65. Hologic has a 12 month low of $51.90 and a 12 month high of $80.31. The firm’s fifty day simple moving average is $71.04 and its 200 day simple moving average is $66.73. The company has a current ratio of 3.55, a quick ratio of 2.81 and a debt-to-equity ratio of 0.52.

Insider Transactions at Hologic

In related news, Director Christiana Stamoulis sold 7,402 shares of the firm’s stock in a transaction dated Monday, October 20th. The shares were sold at an average price of $73.07, for a total value of $540,864.14. Following the completion of the sale, the director directly owned 47,336 shares in the company, valued at approximately $3,458,841.52. This trade represents a 13.52% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Stephen P. Macmillan sold 138,358 shares of Hologic stock in a transaction dated Monday, September 22nd. The stock was sold at an average price of $66.97, for a total value of $9,265,835.26. Following the transaction, the chief executive officer owned 1,234,624 shares of the company’s stock, valued at $82,682,769.28. The trade was a 10.08% decrease in their position. The disclosure for this sale is available in the SEC filing. Company insiders own 1.88% of the company’s stock.

Institutional Trading of Hologic

Several institutional investors and hedge funds have recently bought and sold shares of HOLX. The Manufacturers Life Insurance Company raised its stake in Hologic by 294.3% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 11,022,455 shares of the medical equipment provider’s stock valued at $718,223,000 after acquiring an additional 8,227,318 shares during the period. Invesco Ltd. lifted its stake in shares of Hologic by 72.5% during the 2nd quarter. Invesco Ltd. now owns 8,340,785 shares of the medical equipment provider’s stock worth $543,486,000 after buying an additional 3,505,828 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Hologic by 1.7% during the 2nd quarter. Geode Capital Management LLC now owns 5,828,325 shares of the medical equipment provider’s stock worth $378,209,000 after buying an additional 97,142 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. grew its stake in Hologic by 1.6% in the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,473,098 shares of the medical equipment provider’s stock valued at $276,303,000 after buying an additional 69,878 shares during the last quarter. Finally, Black Creek Investment Management Inc. raised its holdings in Hologic by 26.1% in the 2nd quarter. Black Creek Investment Management Inc. now owns 4,027,829 shares of the medical equipment provider’s stock valued at $262,453,000 after acquiring an additional 832,444 shares during the period. Institutional investors own 94.73% of the company’s stock.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.